Sight Sciences (SGHT) Investor presentation summary

Mission and strategic vision

• Focus on developing transformative interventional technologies to elevate standards of eyecare and empower vision preservation.

• Strategic roadmap targets early intervention for glaucoma and dry eye, aiming to reduce patient burden and improve outcomes.

• Positioned as an innovation leader in two large, underserved markets: interventional glaucoma and interventional dry eye.

Interventional glaucoma market and technology

• Glaucoma affects over 4 million in the U.S., with a $6 billion addressable market; most patients managed with daily drops, often with poor compliance.

• OMNI Surgical System provides comprehensive, implant-free MIGS for POAG, treating all resistance points in the conventional outflow pathway.

• OMNI is supported by robust clinical evidence, FDA indication for standalone or combination cataract procedures, and over 390,000 procedures performed.

• Demonstrated sustained IOP reduction and medication decrease in multiple clinical trials, with efficacy out to three years.

• Addresses all POAG categories, with a $5B standalone and $1B combination cataract MIGS opportunity.

Interventional dry eye market and technology

• Dry eye disease impacts ~19 million in the U.S., with a $2.3 billion market; up to 86% linked to meibomian gland dysfunction (MGD).

• TearCare is the only FDA-cleared, open-eye, thermal-activated gland expression therapy for MGD, with over 70,000 procedures performed.

• SAHARA RCT showed TearCare superior to Restasis in tear breakup time and durable relief for most patients over two years.

• TearCare targets a large, underserved population, with scalable commercial strategy and synergies with glaucoma customer base.